{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:53:49Z","timestamp":1791428029179,"version":"4.3.3"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Patient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years\u2019 total treatment). Patients initially received bimekizumab or secukinumab. At year 1 (week 48\/OLE entry), bimekizumab-randomized patients continued bimekizumab treatment (continuous bimekizumab-treated patients) and secukinumab-randomized patients switched to bimekizumab (secukinumab\/bimekizumab\u2013treated patients).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Continuous bimekizumab-treated patients received bimekizumab, 320 mg, every 4 weeks to week 16, then every 4 weeks or every 8 weeks to 1 year and into the OLE. Secukinumab\/bimekizumab\u2013treated patients received secukinumab, 300 mg, every 4 weeks to 1 year, then switched to bimekizumab, 320 mg, every 4 weeks or every 8 weeks. All received bimekizumab every 8 weeks by week 64.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Patient-reported itching\/skin pain\/scaling (Psoriasis Symptoms and Impacts Measure [P-SIM]) and concurrent achievement of Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores are reported (nonresponder imputation to 1 year; modified nonresponder imputation to 1-3 years).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 373 bimekizumab-treated and 370 secukinumab-treated patients were randomized at baseline; 336 and 318, respectively, entered the OLE. Among bimekizumab-randomized and secukinumab-randomized patients, 127 (34.0%) and 93 (25.1%) reported no itching; 278 (74.5%) and 222 (60.0%) no skin pain; and 172 (46.1%) and 80 (21.6%) no scaling at week 4, respectively; at year 1, rates remained higher in bimekizumab-randomized vs secukinumab-randomized patients (itching: 227 [60.9%] vs 178 [48.1%]; nominal\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; skin pain: 293 [78.6%] vs 262 [70.8%]; nominal\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u2009.01; scaling: 263 [70.5%] vs 184 [49.7%]; nominal\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). Bimekizumab-randomized patients had greater concurrent achievement rates of PASI\u2009=\u20090 and DLQI 0\/1 vs secukinumab-randomized patients (week 4: 43 [11.5%] vs 17 [4.6%]; nominal\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001; year 1: 230 [61.7%] vs 158 [42.7%]; nominal\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). In patients entering the OLE, high P-SIM\u2009=\u20090 rates were maintained to year 3. At OLE entry, concurrent achievement of PASI\u2009=\u20090 and DLQI 0\/1 was reported in 69.2% continuous bimekizumab-treated and 48.5% secukinumab\/bimekizumab\u2013treated patients. After switching, secukinumab\/bimekizumab responses increased, and high rates were maintained to year 3 for both continuous bimekizumab and secukinumab\/bimekizumab (62.2% and 63.8%, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this randomized clinical trial and OLE, bimekizumab rapidly and durably improved symptoms\/health-related quality of life to 3 years, demonstrating that clinical efficacy translates to quality of life improvements. Secukinumab-randomized patients reported improvements on switching to bimekizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/study\/NCT03536884\">NCT03536884<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.6055","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:30:38Z","timestamp":1771432238000},"page":"359","source":"Crossref","is-referenced-by-count":2,"title":["Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis"],"prefix":"10.1001","volume":"162","author":[{"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[{"name":"Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Warren","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Northern Care Alliance NHS Foundation Trust, Salford, Greater Manchester, United Kingdom"},{"name":"Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Vender","sequence":"additional","affiliation":[{"name":"Dermatrials Research Inc., Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"L\u00f3pez-Ferrer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Dawe","sequence":"additional","affiliation":[{"name":"National Psoriasis Foundation, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Lambert","sequence":"additional","affiliation":[{"name":"UCB, Colombes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balint","family":"Szilagyi","sequence":"additional","affiliation":[{"name":"UCB, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Hoepken","sequence":"additional","affiliation":[{"name":"UCB, Monheim am Rhein, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhys","family":"Warham","sequence":"additional","affiliation":[{"name":"Veramed, London, United Kingdom"},{"name":"UCB, Slough, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"doi250075r1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1586\/14737167.2014.914437","article-title":"Quality of life in psoriasis patients.","volume":"14","author":"Augustin","year":"2014","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"doi250075r2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-027535","article-title":"Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry.","volume":"9","author":"Strober","year":"2019","journal-title":"BMJ Open"},{"issue":"3","key":"doi250075r3","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology.","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"doi250075r4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1477-7525-4-35","article-title":"Quality of life in patients with psoriasis.","volume":"4","author":"Bhosle","year":"2006","journal-title":"Health Qual Life Outcomes"},{"key":"doi250075r5","first-page":"553","article-title":"Study on the impact of psoriasis on quality of life: psychological, social and financial implications.","volume":"32","author":"Bulat","year":"2020","journal-title":"Psychiatr Danub"},{"issue":"2","key":"doi250075r6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-020-00363-1","article-title":"Stigmatization and quality of life in patients with psoriasis.","volume":"10","author":"Jankowiak","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3 Pt 1","key":"doi250075r7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0190-9622(99)70112-X","article-title":"Psoriasis causes as much disability as other major medical diseases.","volume":"41","author":"Rapp","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250075r8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.jaad.2020.07.087","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.","volume":"84","author":"Elmets","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi250075r9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00403-018-1808-x","article-title":"Treatment preferences and treatment satisfaction among psoriasis patients: a systematic review.","volume":"310","author":"Florek","year":"2018","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"doi250075r10","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations.","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi250075r11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F.","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"issue":"10273","key":"doi250075r12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"doi250075r13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis.","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"doi250075r14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis.","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"doi250075r15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/bjd\/ljaf032","article-title":"Bimekizumab efficacy and safety through 3?years in patients with moderate-to-severe plaque psoriasis: long-term results from the BE RADIANT phase IIIb trial open-label extension period.","volume":"193","author":"Warren","year":"2025","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi250075r16","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jaad.2025.04.038","article-title":"Bimekziumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.","volume":"93","author":"Blauvelt","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250075r17","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.jaad.2023.04.063","article-title":"Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.","volume":"89","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi250075r18","doi-asserted-by":"publisher","first-page":"5253","DOI":"10.1007\/s12325-021-01836-1","article-title":"Psychometric validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): a novel patient-reported outcome instrument for patients with plaque psoriasis, using reported data from the BE RADIANT phase 3b trial.","volume":"38","author":"Gottlieb","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"doi250075r19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41687-017-0004-7","article-title":"The content validity of the PSS in patients with plaque psoriasis.","volume":"1","author":"Rentz","year":"2017","journal-title":"J Patient Rep Outcomes"},{"issue":"4","key":"doi250075r20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamadermatol.2023.6245","article-title":"Identifying core outcome domains in chronic skin disease using the best-worst scaling method.","volume":"160","author":"Shields","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi250075r21","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s13555-021-00570-4","article-title":"Psychometric validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome instrument for patients with plaque psoriasis, using data from the BE VIVID and BE READY phase 3 trials.","volume":"11","author":"Warren","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"doi250075r22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s13555-020-00434-3","article-title":"Development and content validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for assessment of plaque psoriasis.","volume":"10","author":"Gottlieb","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi250075r23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"doi250075r24","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","article-title":"Translating the science of quality of life into practice: what do Dermatology Life Quality Index scores mean?","volume":"125","author":"Hongbo","year":"2005","journal-title":"J Invest Dermatol"},{"issue":"6","key":"doi250075r28","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/bjd.20595","article-title":"Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.","volume":"185","author":"Papp","year":"2021","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi250075r29","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials.","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"doi250075r30","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/s13555-021-00545-5","article-title":"Dermatology Life Quality Index in patients with moderate-to-severe plaque psoriasis treated with brodalumab or ustekinumab.","volume":"11","author":"Lambert","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"doi250075r31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaad.2016.10.017","article-title":"From the Medical Board of the National Psoriasis Foundation: treatment targets for plaque psoriasis.","volume":"76","author":"Armstrong","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"doi250075r32","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","article-title":"Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis.","volume":"14","author":"Augustin","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"doi250075r25","unstructured":"Cardiff University. Dermatology Life Quality Index. 2024. Accessed March 2025. https:\/\/www.cardiff.ac.uk\/medicine\/resources\/quality-of-life-questionnaires\/dermatology-life-quality-index"},{"key":"doi250075r26","unstructured":"European Medicines Agency. Summary of product characteristics. 2021. Accessed March 2025. https:\/\/www.medicines.org.uk\/emc\/product\/12833\/smpc#gref"},{"key":"doi250075r27","unstructured":"US Food and Drug Administration. Bimzelx\u00ae US prescribing information. 2023. Accessed March 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761151s000lbl.pdf"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2845196\/jamadermatology_augustin_2026_oi_250075_1775760785.58479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:00:35Z","timestamp":1776265235000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2845196"}},"subtitle":["The BE RADIANT Randomized Clinical Trial With Open-Label Extension"],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.6055","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}